Kerendia® (finerenone) 10- and 20-mg tablets

_{Prespecified pooled analysis}

In adult patients with CKD and T2D

A robust safety profile for Kerendia was demonstrated in >13,000 patients

The most commonly reported AE with Kerendia was hyperkalaemia

Treatment-emergent AE	Kerendia % (n=6510)	Placebo % (n=6489)
Any AE	86.1 (5602)	86.4 (5607)
Any serious AE	31.6 (2060)	33.7 (2186)
Hyperkalaemia	14.0 (912)	6.9 (448)
Leading to hospitalisation	0.9 (61)	0.2 (10)
Leading to permanent treatment discontinuation	1.7 (110)	0.6 (38)
Leading to death	0	0

Hormonal symptoms were similar between Kerendia and placebo, respectively

Gynaecomastia 0.1% (8) vs 0.2% (11)	Reproductive system and breast disorder 5.6% (362) vs 5.6% (361)	Breast hyperplasia 0% vs <0.1% (5)

_{Findings from a prespecified pooled safety analysis demonstrate}

Abbreviations
^*The effects of Kerendia and placebo on mean SBP (pooled safety analysis set). Data are shown as mean ± standard deviation.
^†Hypotension was reported more commonly with Kerendia than with placebo and in ≥1% of patients treated with Kerendia.

AE=adverse event; CKD=chronic kidney disease; HbA1c=glycated haemoglobin; SBP=systolic blood pressure; T2D=type 2 diabetes.